Pasireotide treatment does not modify hyperglycemic and corticosterone acute restraint stress responses in rats
- 17 April 2018
- journal article
- research article
- Published by Taylor & Francis in Stress
- Vol. 21 (4) , 370-375
Abstract
Pasireotide is a new-generation somatostatin analog that acts through binding to multiple somatostatin receptor subtypes. Studies have shown that pasireotide induces hyperglycemia, reduces glucocorticoid secretion, alters neurotransmission, and potentially affects stress responses typically manifested as hyperglycemia and increased corticosterone secretion. This study specifically aimed to evaluate whether pasireotide treatment modifies glucose and costicosterone secretion in response to acute restraint stress. Male Holtzman rats of 150–200 g were treated with pasireotide (10 µg/kg/day) twice-daily for two weeks or vehicle for the same period. Blood samples were collected at baseline and after 5, 10, 30, and 60 min of restraint stress. The three experimental groups comprised of vehicle + restraint (VEHR), pasireotide + restraint (PASR), and pasireotide + saline (PASNR). Following pasireotide treatment, no significant differences in baseline glucose and corticosterone levels were observed among the three groups. During restraint, hyperglycemia was observed at 10 min (p < .01 for both comparisons), peaked at 30 min (p < .01 for both comparisons) and showed higher 60 min areas under glucose curves in the VEHR and PASR stressed groups when compared to the non-stressed PASNR group (p < .05 for both comparisons). Restraint also increased corticosterone secretion in the VEHR and PASR stressed groups at 5 min (p < .01 for both comparisons), and peaked at 30 min (p < .01 for both comparisons) with corresponding higher 60 min areas under corticosterone curves when compared to the non-stressed PASNR group (p < .01 for both comparisons). In conclusion, pasireotide treatment does not modify hyperglycemic- and corticosterone-restraint stress responses, thus preserving acute stress regulation.Keywords
Funding Information
- CNPq
- FAPEMIG
This publication has 27 references indexed in Scilit:
- A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteersDrug Design, Development and Therapy, 2012
- Effects of somatostatin analogs on glucose homeostasis in ratsJournal of Endocrinology, 2011
- Ligand-Dependent Mechanisms of sst2A Receptor Trafficking: Role of Site-Specific Phosphorylation and Receptor Activation in the Actions of Biased Somatostatin AgonistsMolecular Endocrinology, 2011
- Effect of SOM230 (Pasireotide) on Corticotropic Cells: Action in Dogs with Cushing’s DiseaseNeuroendocrinology, 2011
- Angiotensin-converting enzyme inhibition changes the metabolic response to neuroglucopenic stressJournal of the Renin-Angiotensin-Aldosterone System, 2011
- Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling PathwaysMolecular Endocrinology, 2010
- Pituitary‐Adrenal Response to Acute and Repeated Mild Restraint, Forced Swim and Change in Environment Stress in Arginine Vasopressin Receptor 1b Knockout MiceJournal of Neuroendocrinology, 2008
- Opportunities in somatostatin research: biological, chemical and therapeutic aspectsNature Reviews Drug Discovery, 2003
- Somatostatin and Its Receptor FamilyFrontiers in Neuroendocrinology, 1999
- Blood glucose and prolactin in hyperprolactinemic rats exposed to restraint and surgical stressLife Sciences, 1995